The Centre for Advanced Medical Products (CAMP, an initiative of Vinnova) has decided to proceed on the project titled: `Establishing a non-dry ice dependent logistics strategy for cell therapies". The goal of this project is to evaluate the best logistics strategy for cell-based products. This can be done by evaluating various transportation methods, mechanisms of traceability and quality control. For NextCell specifically it also allows to validate the robustness of several functional and potency assays in a tech transfer, that can increase the viability and quality of mesenchymal stem cell treatments.

NextCell"s drug candidate based on stem cells, ProTrans, has shown promising results for the treatment of type 1 diabetes in an interim analysis of the patients who participated in the dose scaling section. The phase 2 part will be completed this summer and NextCell is now preparing the progression of the clinical development program with the aim of obtaining market approval for ProTrans. An optimal logistics for frozen stem cells is of the utmost importance in major clinical trials, but above all in order to be able to deliver ProTrans to patients worldwide.

NextCell will gain access to the expertise and skills of RISE and YSDS enabling to perform work and analysis that the company otherwise would need to contract and pay for to get done. The project itself is largely co-funded in-kind (salaries, office space etc.) by the participants. The total budget for the entire project is about 1.075.000 SEK. NextCell contributes with 250.000 SEK, fully co-funded in-kind.

NextCell has now also formally joined CAMP, founded by Vinnova and a leading Swedish consortium of stakeholders, from different backgrounds such as; SMEs, big pharma, universities, research organizations and county councils. All participants are active in the field of Advanced Therapy Medicinal Products (ATMPs) and together aim to accelerate a more competitive Swedish landscape for the development, production, market introduction and reimbursement of ATMPs.

Stay up to date with the latest development in NextCell Pharma

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595

E-mail: info@nextcellpharma.com

Website:

www.nextcellpharma.com, www.cellaviva.se

www.cellaviva.se

www.cellaviva.dk

About NextCell Pharma AB:

Stem cells are expected to change the way how many of today"s life-threatening diseases are treated. NextCell

Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB"s proprietary method. In addition, the company has a service called Cellaviva, Scandinavia"s largest stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.